Anaplastic thyroid carcinoma, version 2.2015 Journal Article
| Authors: | Haddad, R. I.; Lydiatt, W. M.; Ball, D. W.; Busaidy, N. L.; Byrd, D.; Callender, G.; Dickson, P.; Duh, Q. Y.; Ehya, H.; Haymart, M.; Hoh, C.; Hunt, J. P.; Iagaru, A.; Kandeel, F.; Kopp, P.; Lamonica, D. M.; McCaffrey, J. C.; Moley, J. F.; Parks, L.; Raeburn, C. D.; Ridge, J. A.; Ringel, M. D.; Scheri, R. P.; Shah, J. P.; Smallridge, R. C.; Sturgeon, C.; Wang, T. N.; Wirth, L. J.; Hoffmann, K. G.; Hughes, M. |
| Article Title: | Anaplastic thyroid carcinoma, version 2.2015 |
| Abstract: | This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Thyroid Carcinoma focuses on anaplastic carcinoma because substantial changes were made to the systemic therapy recommendations for the 2015 update. Dosages and frequency of administration are now provided, docetaxel/doxorubicin regimens were added, and single-agent cisplatin was deleted because it is not recommended for patients with advanced or metastatic anaplastic thyroid cancer. © JNCCN-Journal of the National Comprehensive Cancer Network. |
| Keywords: | cancer chemotherapy; review; intensity modulated radiation therapy; advanced cancer; systemic therapy; cancer radiotherapy; antineoplastic agent; cancer incidence; metastasis; practice guideline; cancer mortality; distant metastasis; thyroidectomy; thyroid carcinoma; external beam radiotherapy; cytopathology; differentiated thyroid cancer; anaplastic thyroid cancer; cancer prognosis; human |
| Journal Title: | Journal of the National Comprehensive Cancer Network |
| Volume: | 13 |
| Issue: | 9 |
| ISSN: | 1540-1405 |
| Publisher: | Harborside Press |
| Date Published: | 2015-09-01 |
| Start Page: | 1140 |
| End Page: | 1150 |
| Language: | English |
| PROVIDER: | scopus |
| PUBMED: | 26358798 |
| PMCID: | PMC4986600 |
| DOI/URL: | |
| Notes: | Export Date: 2 October 2015 -- Source: Scopus |
